J&J: Thoughts On Sirukumab And Other Problems

9/24/17

Johnson & Johnson has become an expensive stock with limited growth prospects.

Its appeal has centered around dividend growth prospects (aka bond substitute) anchored by an AAA credit rating and a squeaky clean image.

However, repeated guilty pleas for corporate misbehavior challenge that image; several large or even massive punitive judgments in product liability suits may put the credit rating at risk.

The company's actions with regard to its pipeline RA drug sirukumab have added to the above issues.

READ FULL ARTICLE HERE

Recent Deals

Interested in advertising your deals? Contact Edwin Warfield.